Novartis Declares End of HSR Act Waiting Period for Tourmaline Bio Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Novartis Acquisition Announcement: Novartis has announced a tender offer to acquire all outstanding shares of Tourmaline Bio at a price of $48.00 per share in cash.
HSR Act Waiting Period Expiration: The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on October 21, 2025, allowing the acquisition process to move forward.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVS is 129.00 USD with a low forecast of 118.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 141.610
Low
118.00
Averages
129.00
High
140.00
Current: 141.610
Low
118.00
Averages
129.00
High
140.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
